ID   OVCA432
AC   CVCL_3769
SY   OV-CA 432; OVCA 432; OvCA 432; OVCA-432; OVCA432_Bast; OVCAR-432; OVCAR 432; OVCAR432
DR   BTO; BTO:0002565
DR   CLO; CLO_0008278
DR   EFO; EFO_0006722
DR   CLDB; cl3778
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03470830
DR   cancercelllines; CVCL_3769
DR   Cosmic; 924147
DR   Cosmic; 991322
DR   Cosmic; 1524354
DR   EGA; EGAS00001000610
DR   GDSC; 1480366
DR   GEO; GSM659392
DR   GEO; GSM711705
DR   GEO; GSM851930
DR   GEO; GSM2474991
DR   IARC_TP53; 28488
DR   PharmacoDB; OvCA432_1215_2019
DR   Wikidata; Q54936988
RX   PubMed=1536252;
RX   PubMed=6346879;
RX   PubMed=7028788;
RX   PubMed=7836420;
RX   PubMed=10318951;
RX   PubMed=10972993;
RX   PubMed=11793438;
RX   PubMed=12960427;
RX   PubMed=20204287;
RX   PubMed=22585861;
RX   PubMed=22710073;
RX   PubMed=23415752;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=28273451;
CC   Doubling time: 37.09 hours (GrayJW panel).
CC   HLA typing: A*01:01,29:02; B*44:03,55:01; C*03:03,16:01; DQB1*02:02,03:02; DRB1*07:01,11:79 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Phe (c.830G>T); ClinVar=VCV000458567; Zygosity=Unspecified (PubMed=20204287; PubMed=28273451).
CC   Omics: Array-based CGH.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): PubMed=22710073; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11,12
ST   D16S539: 12
ST   D18S51: 15,16
ST   D19S433: 12,15
ST   D21S11: 29,31.2
ST   D2S1338: 20,24
ST   D3S1358: 16
ST   D5S818: 12,13
ST   D7S820: 8,10
ST   D8S1179: 10,14
ST   FGA: 20,24
ST   Penta D: 10,14
ST   Penta E: 13,19
ST   TH01: 10
ST   TPOX: 11
ST   vWA: 15,19
DI   NCIt; C7550; Ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_IQ28 ! LAZ-446
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   PubMed=1536252; DOI=10.1016/0002-9378(92)91697-9;
RA   Berchuck A., Rodriguez G., Olt G., Whitaker R., Boente M.P.,
RA   Arrick B.A., Clarke-Pearson D.L., Bast R.C. Jr.;
RT   "Regulation of growth of normal ovarian epithelial cells and ovarian
RT   cancer cell lines by transforming growth factor-beta.";
RL   Am. J. Obstet. Gynecol. 166:676-684(1992).
//
RX   PubMed=6346879; DOI=10.1016/0002-9378(83)90999-7;
RA   Berkowitz R.S., Kabawat S., Lazarus H., Colvin R.B., Knapp R.C.,
RA   Bast R.C. Jr.;
RT   "Comparison of a rabbit heteroantiserum and a murine monoclonal
RT   antibody raised against a human epithelial ovarian carcinoma cell
RT   line.";
RL   Am. J. Obstet. Gynecol. 146:607-612(1983).
//
RX   PubMed=7028788; DOI=10.1172/JCI110380;
RA   Bast R.C. Jr., Feeney M., Lazarus H., Nadler L.M., Colvin R.B.,
RA   Knapp R.C.;
RT   "Reactivity of a monoclonal antibody with human ovarian carcinoma.";
RL   J. Clin. Invest. 68:1331-1337(1981).
//
RX   PubMed=7836420; DOI=10.1074/jbc.270.3.999;
RA   Young T.N., Pizzo S.V., Stack M.S.;
RT   "A plasma membrane-associated component of ovarian adenocarcinoma
RT   cells enhances the catalytic efficiency of matrix metalloproteinase-2.";
RL   J. Biol. Chem. 270:999-1002(1995).
//
RX   PubMed=10318951; DOI=10.1073/pnas.96.10.5722;
RA   Lau K.-M., Mok S.C., Ho S.-M.;
RT   "Expression of human estrogen receptor-alpha and -beta, progesterone
RT   receptor, and androgen receptor mRNA in normal and malignant ovarian
RT   epithelial cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:5722-5727(1999).
//
RX   PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H;
RA   Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.;
RT   "Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon
RT   12 deletion variant in malignant human ovarian, prostate, and breast
RT   cancer cell lines.";
RL   Mol. Carcinog. 28:236-246(2000).
//
RX   PubMed=11793438; DOI=10.1002/gcc.1221;
RA   Rao P.H., Harris C.P., Lu X.-Y., Li X.-N., Mok S.C., Lau C.C.;
RT   "Multicolor spectral karyotyping of serous ovarian adenocarcinoma.";
RL   Genes Chromosomes Cancer 33:123-132(2002).
//
RX   PubMed=12960427; DOI=10.1091/mbc.E03-05-0279;
RA   Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.G.,
RA   Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H.,
RA   Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J.,
RA   Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R.,
RA   van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O.,
RA   Sikic B.I.;
RT   "Gene expression patterns in ovarian carcinomas.";
RL   Mol. Biol. Cell 14:4376-4386(2003).
//
RX   PubMed=20204287; DOI=10.3892/or_00000728;
RA   Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H.,
RA   Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.;
RT   "Radiosensitivity profiles from a panel of ovarian cancer cell lines
RT   exhibiting genetic alterations in p53 and disparate DNA-dependent
RT   protein kinase activities.";
RL   Oncol. Rep. 23:1021-1026(2010).
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//